As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

On this weeks Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a ...

Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

Created exclusively for the leaders of new and emerging biopharma firms, The Business of Biotech tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from ...

The business model CEO Dr. Hernan Bazan and his colleagues put in place at South Rampart Pharma was not typical for a small biotech firm.

503B compounders require special attention to maintain cGMP and regulation compliance. Examine the process for designing and managing new facilities for sterile and parenteral injectable manufacturing ...

Executive Interviews: Life Science LeaderAccelerating Drug Development With Real World Data Think real-world data’s only application is clinical trials? Think again. Savvy early-stage biotechs are ...

Companies To Watch: Vivani Medical Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The company's ...

Here’s how to ensure you’re successfully maximizing that infusion of money and setting yourself up for further success in the grant world.

With the enthusiasm surrounding innovative product types and therapeutic approaches — and the corresponding rush to bring these new products to market — company leaders should double down on internal ...